-
Information-Publications
-
Nur77-IRF1 axis inhibits esophageal squamous cell carcinoma growth and improves anti-PD-1 treatment efficacyDetails -
Investigation on the Pathological Mechanism of Frequent Exacerbators With Chronic Obstructive Pulmonary Disease Based on the Characteristics of …Details -
Rearranged Dichapetalin‐Type Triterpenoids with Cytotoxic Activity from Dichapetalum gelonioidesDetails -
PDTAC: Targeted photodegradation of GPX4 triggers Ferroptosis and potent antitumor immunityDetails -
Chronic exposure to the gibberellin derivative GA‑13315 sensitizes breast cancer MCF‑7 cells but not colon cancer HCT116 cells to irinotecanDetails -
New perspectives on the potential of tetrandrine in the treatment of non-small cell lung cancer: bioinformatics, Mendelian randomization study and …Details
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands
Back
